A BILL 
To increase the number of manufacturers registered under 
the Controlled Substances Act to manufacture cannabis 
for legitimate research purposes, to authorize health care 
providers of the Department of Veterans Affairs to pro-
vide recommendations to veterans regarding participation 
in federally approved cannabis clinical trials, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
19:47 Feb 04, 2019
H601
2 
•HR 601 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Medical Cannabis Re-
2
search Act of 2019’’. 
3
SEC. 2. INCREASING THE NUMBER OF FEDERALLY REG-
4
ISTERED 
MANUFACTURERS 
OF 
CANNABIS 
5
FOR LEGITIMATE RESEARCH PURPOSES. 
6
(a) IN GENERAL.—Section 303 of the Controlled 
7
Substances Act (21 U.S.C. 823) is amended— 
8
(1) by redesignating subsection (k) as sub-
9
section (l); and 
10
(2) by inserting after subsection (j) the fol-
11
lowing: 
12
‘‘(k) REGISTRATION OF MANUFACTURERS OF CAN-
13
NABIS FOR LEGITIMATE RESEARCH PURPOSES.— 
14
‘‘(1) IN GENERAL.—Any manufacturer of can-
15
nabis for research shall obtain a separate registra-
16
tion under this subsection for that purpose— 
17
‘‘(A) annually; or 
18
‘‘(B) for a longer period as determined 
19
necessary by the Attorney General to supply 
20
cannabis for the full duration of a particular 
21
multi-year study for legitimate research pur-
22
poses. 
23
‘‘(2) ADEQUATE
AND
UNINTERRUPTED
SUP-
24
PLY.— 
25
19:47 Feb 04, 2019
H601
3 
•HR 601 IH
‘‘(A) ANNUAL
ASSESSMENT.—On an an-
1
nual basis, the Attorney General shall assess 
2
whether there is an adequate and uninterrupted 
3
supply of cannabis for legitimate research pur-
4
poses. 
5
‘‘(B) INITIAL
YEAR.—Not later than 1 
6
year after the date of enactment of the Medical 
7
Cannabis Research Act of 2019, of the appli-
8
cants meeting the requirements of this Act, the 
9
Attorney General shall register under sub-
10
section (a) and this subsection at least 3 appli-
11
cants to manufacture cannabis for legitimate 
12
research purposes in addition to any manufac-
13
turers that are registered under subsection (a) 
14
to manufacture cannabis as of the date of en-
15
actment of the Medical Cannabis Research Act 
16
of 2019. 
17
‘‘(C) SUBSEQUENT YEARS.—For calendar 
18
year 2019 and each subsequent calendar year, 
19
of the applicants meeting the requirements of 
20
this Act, the Attorney General shall register 
21
(including any registration renewal) under sub-
22
section (a) and this subsection at least 4 appli-
23
cants to manufacture cannabis for legitimate 
24
research purposes. 
25
19:47 Feb 04, 2019
H601
4 
•HR 601 IH
‘‘(3) REQUIREMENTS.—A manufacturer reg-
1
istered under this subsection shall— 
2
‘‘(A) comply with all applicable require-
3
ments of this Act; 
4
‘‘(B) limit the transfer and sale of any 
5
cannabis manufactured pursuant to this sec-
6
tion— 
7
‘‘(i) to researchers who are registered 
8
under this Act to conduct research with 
9
controlled substances in schedule I; and 
10
‘‘(ii) for purposes of use in preclinical 
11
research or in a clinical investigation pur-
12
suant to an investigational new drug ex-
13
emption under 505(i) of the Federal Food, 
14
Drug, and Cosmetic Act; 
15
‘‘(C) have completed the application and 
16
review process under subsection (a) for the bulk 
17
manufacture of controlled substances in sched-
18
ule I; 
19
‘‘(D) have established and begun operation 
20
of a process for storage and handling of con-
21
trolled substances in schedule I, including for 
22
inventory control and monitoring security; 
23
‘‘(E) have the ability to provide at least 10 
24
unique plant cultivars to ensure plant diversity 
25
19:47 Feb 04, 2019
H601
5 
•HR 601 IH
and scale up to produce bulk plant material on 
1
an uninterrupted basis sufficient to supply fore-
2
casted demand; 
3
‘‘(F) be licensed, by each State in which 
4
the manufacturer conducts its operations pursu-
5
ant to this subsection, to manufacture cannabis; 
6
‘‘(G) have completed a criminal back-
7
ground check for all personnel involved in the 
8
operations of the manufacturer pursuant to this 
9
subsection to confirm that such personnel have 
10
no conviction for a violent felony; and 
11
‘‘(H) have the ability to test for and isolate 
12
at least 12 cannabinoids for the purposes of 
13
producing specific products for specific studies 
14
by compounding pharmacists or others, label-
15
ing, and chemical consistency. 
16
‘‘(4) APPLICATION CONTENTS.—As part of an 
17
application to be registered under this subsection, an 
18
applicant shall include a written explanation of how 
19
the applicant’s proposed manufacture of cannabis 
20
would augment the Nation’s supply of cannabis for 
21
legitimate research purposes. 
22
‘‘(5) PROCESS.—Not later than 1 year after the 
23
date on which the Attorney General receives an ap-
24
plication to be registered under this section to man-
25
19:47 Feb 04, 2019
H601
6 
•HR 601 IH
ufacture cannabis for research, the Attorney General 
1
shall— 
2
‘‘(A) grant, or initiate proceedings under 
3
section 304(c) to deny, the application; or 
4
‘‘(B) request supplemental information 
5
from the applicant. 
6
‘‘(6) RULE OF CONSTRUCTION ON REGISTRA-
7
TION
FOR
PURPOSES
OTHER
THAN
RESEARCH.— 
8
Nothing in this subsection shall be construed to af-
9
fect the provisions of this section prohibiting or oth-
10
erwise pertaining to registration of manufacturers of 
11
cannabis for purposes other than research, including 
12
for purposes of strictly commercial endeavors funded 
13
by the private sector and aimed at drug product de-
14
velopment. 
15
‘‘(7) NO DISCRIMINATORY TREATMENT BY FED-
16
ERAL
GOVERNMENT.—Notwithstanding any other 
17
provision of law, no Federal department or agency 
18
shall deny or limit any funding, other assistance, li-
19
censing, or other privilege with respect to any person 
20
on the basis that such person is, or is legally receiv-
21
ing cannabis from, a manufacturer of cannabis that 
22
is— 
23
‘‘(A) registered under this subsection; and 
24
19:47 Feb 04, 2019
H601
7 
•HR 601 IH
‘‘(B) in compliance with the requirements 
1
of this Act. 
2
‘‘(8) SPECIAL RULE.—If cannabis, or any com-
3
ponent thereof, is placed in a schedule other than 
4
schedule I, the Attorney General may, as the Attor-
5
ney General determines appropriate— 
6
‘‘(A) treat the reference to ‘subsection (a)’ 
7
in paragraph (2)(C) of this subsection as a ref-
8
erence to subsection (d); and 
9
‘‘(B) treat the references to schedule I in 
10
paragraph (3) as references to the appropriate 
11
schedule. 
12
‘‘(9) DEFINITION.—In this subsection, the term 
13
‘legitimate research purposes’ has the meaning given 
14
to such term for purposes of subsection (a)(1).’’. 
15
(b) TRANSITIONAL PROVISIONS.— 
16
(1) CURRENT REGISTRANTS.—Notwithstanding 
17
paragraph (1) of section 303(k) of the Controlled 
18
Substances Act, as added by subsection (a), any 
19
manufacturer that is registered under section 303(a) 
20
of the Controlled Substances Act (21 U.S.C. 823(a)) 
21
to manufacture cannabis as of the date of enactment 
22
of this Act shall not be required to obtain a separate 
23
registration under such section 303(k) for the 1-year 
24
period following the date of enactment of this Act. 
25
19:47 Feb 04, 2019
H601
8 
•HR 601 IH
(2) PENDING APPLICATIONS.—Except as pro-
1
vided in paragraph (1), the Attorney General of the 
2
United States shall grant or deny, in accordance 
3
with section 303 of the Controlled Substances Act 
4
(21 U.S.C. 823), as amended by subsection (a), each 
5
application to manufacture cannabis to supply re-
6
searchers in the United States that was submitted— 
7
(A) pursuant to the policy statement enti-
8
tled ‘‘Applications To Become Registered Under 
9
the Controlled Substances Act To Manufacture 
10
Marijuana To Supply Researchers in the United 
11
States’’ published by the Drug Enforcement 
12
Administration in the Federal Register on Au-
13
gust 12, 2016 (81 Fed. Reg. 53846); and 
14
(B) before the date of enactment of this 
15
Act. 
16
(c) TECHNICAL AMENDMENT.—Section 102(16) of 
17
the Controlled Substances Act (21 U.S.C. 802(16)) is 
18
amended by inserting after ‘‘The term ‘marihuana’ ’’ the 
19
following: ‘‘or ‘marijuana’ or ‘cannabis’ ’’. 
20
19:47 Feb 04, 2019
H601
9 
•HR 601 IH
SEC. 3. PROVISION BY DEPARTMENT OF VETERANS AF-
1
FAIRS HEALTH CARE PROVIDERS OF INFOR-
2
MATION REGARDING VETERAN PARTICIPA-
3
TION IN FEDERALLY APPROVED CANNABIS 
4
CLINICAL TRIALS. 
5
(a) PROVISION OF INFORMATION AND FORMS.—Not-
6
withstanding any other provision of law, health care pro-
7
viders of the Department of Veterans Affairs may— 
8
(1) provide information to veterans regarding 
9
participation in federally approved cannabis clinical 
10
trials; and 
11
(2) complete forms relating to such participa-
12
tion. 
13
(b) RECEIPT OF INFORMATION.—Health care pro-
14
viders and other employees of the Department may accept 
15
information regarding federally approved cannabis clinical 
16
trials provided by individuals who are not employed by the 
17
Department who are researchers registered under the 
18
Controlled Substances Act (21 U.S.C. 801 et seq.) to con-
19
duct research with controlled substances in schedule I of 
20
section 202(c) of such Act (21 U.S.C. 812(c)). 
21
(c) RESEARCH.—The Secretary of Veterans Affairs 
22
may conduct research on cannabis if the employees of the 
23
Department who are conducting such research are re-
24
searchers registered under the Controlled Substances Act 
25
(21 U.S.C. 801 et seq.) to conduct research with con-
26
19:47 Feb 04, 2019
H601
10 
•HR 601 IH
trolled substances in schedule I of section 202(c) of such 
1
Act (21 U.S.C. 812(c)). 
2
Æ 
19:47 Feb 04, 2019
H601
